Business Impact of the COVID-19 Pandemic
First written in FY2020-Q3. 8 of 17 entries say "Mitigated", first in FY2022. Latest entry: FY2024.
OLBA DVx HEALTHCARE moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
51 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「Sales of consumables related to surgery declined as demand for testing-related products and infection-control products fell with the subsiding of COVID-19, down 6.6% and 9.2%, respectively, from the previous fiscal year. Meanwhile, sales of core surgical products increased 10.2% year on year, while sales of anesthesia-related products used in surgery increased 11.3%.」
The impact of COVID-19-related postponement of surgeries weakened, and core surgical and anesthesia-related products generated higher revenue, while testing and infection-control products shifted to lower demand. - FY2024-Q3MitigatedAnnual report
「Sales of consumables related to surgery declined as demand for testing-related products and infection-control products fell with the subsiding of COVID-19, down 7.7% and 11.1%, respectively, year on year. Meanwhile, sales of core surgical products increased 10.2% year on year, sales of anesthesia-related products used in surgery increased 12.2%, and sales of gastrointestinal endoscopy-related products increased 26.7% through the company's initiative with Olympus Marketing in Fukushima Prefecture.」
The impact of COVID-19-related postponement of surgeries weakened, and core surgical, anesthesia, and gastrointestinal endoscopy-related products generated higher revenue. Although demand for infection-control products and other items remained lower, the business as a whole continued to recover from and transition away from the impact of COVID-19. - FY2024-Q2MitigatedAnnual report
「Sales of consumables related to surgery had almost recovered from the impact of fewer surgeries due to COVID-19, increasing 2.8% year on year.」
Consumables related to surgery had almost recovered from the impact of fewer surgeries due to COVID-19, increasing 2.8% year on year. Demand for infection-control products and other items remained lower as COVID-19 subsided. - FY2023MitigatedAnnual report
「Although COVID-19 continued to affect the number of surgeries, we believe that the number of surgeries has generally returned to pre-COVID-19 levels as vaccination rates have improved, infection-control measures at medical institutions have advanced, and COVID-19 was reclassified as a Class 5 infectious disease under the Infectious Diseases Control Law, among other factors.」
Although the impact of COVID-19-related postponement of surgeries remains, surgical volumes generally returned to pre-COVID-19 levels against the backdrop of the transition to Category 5 and progress in infection-control measures, and the previous business impact had diminished. - FY2023-Q3MitigatedAnnual report
「Sales of consumables related to surgery had almost recovered from the impact of fewer surgeries due to COVID-19, increasing 2.8% year on year.」
Consumables related to surgery had almost recovered from the impact of fewer surgeries due to COVID-19, increasing 2.8% year on year. The company states that the impact of COVID-19 remains in some areas, including cardiovascular products. - FY2023-Q2MitigatedAnnual report
「The impact of COVID-19, currently in its eighth wave, on the number of surgeries has weakened considerably compared with the initial period. Although medical institutions where clusters have occurred may temporarily have no choice but to restrict surgeries, the number of surgeries overall has largely returned to pre-COVID-19 levels due to factors including a higher vaccination rate and progress in infection-control measures within medical institutions.」
The company states that the impact of COVID-19 on surgical volumes has weakened considerably from the initial stage and that volumes have generally returned to pre-COVID-19 levels. Meanwhile, the possibility of temporary restrictions due to the eighth wave and clusters at healthcare institutions remains. - FY2023-Q1MitigatedAnnual report
「COVID-19 continued to affect surgical volumes, but we believe that they have now generally returned to pre-COVID-19 levels as vaccination rates have improved and infection-control measures at healthcare institutions have advanced.」
Although the impact of COVID-19 on surgical volumes remains, the company believes that volumes have generally returned to pre-COVID-19 levels and that the previous impact of postponed surgeries has diminished. - FY2022MitigatedAnnual report
「The number of surgeries affecting performance in the core medical equipment business is gradually recovering toward pre-COVID-19 levels.」
The company states that although the impact of COVID-19-related postponement of surgeries remains, surgical volumes are gradually recovering toward pre-COVID-19 levels, and sales and profit in the medical equipment business have increased. - FY2022-Q3Surgical volumes recovering, while the risk of renewed expansion and impacts by area continueAnnual report
「A future resurgence of COVID-19 could reduce sales of products related to trauma, sports medicine, and arthroscopy, which are more sensitive to levels of human activity, but demand for orthopedic consumables overall continues to trend upward.」
While demand for orthopedic consumables overall began to trend upward as surgical volumes recovered, the company continues to note the possibility of lower revenue from products related to trauma, sports medicine, and arthroscopy due to a renewed spread of COVID-19. - FY2022-Q2Surgical volumes recovering, while the risk of renewed expansion and impacts by area continueAnnual report
「However, surgical volumes have been trending upward since around autumn 2021, owing to progress in the division of roles and coordination among healthcare institutions, higher vaccination rates, and advances in infection control within healthcare institutions.」
Surgical volumes began to recover around autumn 2021 as coordination among healthcare institutions, vaccination, and infection-control measures within hospitals progressed. Meanwhile, the company stated that renewed spread of COVID-19 could reduce sales of products related to trauma, sports medicine, and arthroscopy, and that impacts by area were continuing. - FY2022-Q1Surgical volumes recovering, while COVID-19 impacts continue by areaAnnual report
「Healthcare institutions required to secure beds dedicated to COVID-19 patients have been forced to take various measures, including consolidating clinical functions and strengthening coordination between hospitals and clinics. As a result, the number of surgeries had tended to decline, particularly for chronic diseases, but has recently begun to recover gradually as healthcare institutions have advanced their infection-control measures. Sales of consumables in the medical equipment business increased 2.3% year on year.」
While the consolidation of clinical functions and postponement of surgeries due to COVID-19 continued, surgical volumes gradually recovered as healthcare institutions advanced their infection-control measures. The impact of lower revenue remains in orthopedics and some cardiovascular fields. - FY2021MaterialisedAnnual report
「Looking at the overall impact of COVID-19 during the period, the number of surgeries, which affects performance in the medical equipment business, continued to decline, and the company estimates that the impact was approximately ¥2.4 billion in terms of sales. However, increased demand for infection-control products, represented by PPE (personal protective equipment such as masks and gloves), and testing-related products, together with orders for equipment used in COVID-19 countermeasures, made up for the shortfall in these sales.」
The company estimates the impact of COVID-19 from fewer surgeries at approximately ¥2.4 billion in sales. It states that increased demand for PPE, testing-related products, and equipment used in COVID-19 countermeasures made up for the shortfall. - FY2021-Q3MaterialisedAnnual report
「Sales of total consumables, a growth driver, fell 2.5% year on year as a result of the continued impact of fewer surgeries accompanying the spread of COVID-19, hereinafter "COVID-19."」
The impact of fewer surgeries due to the spread of COVID-19 continued through the cumulative third quarter, with total sales of consumables down 2.5% year on year. Meanwhile, demand increased for equipment and fixtures, including PPE and PCR testing equipment related to COVID-19 countermeasures. - FY2021-Q2MaterialisedAnnual report
「Total consumables revenue, the growth driver, decreased 2.7% year on year, continuing to be affected by the decline in surgical cases associated with the spread of COVID-19.」
The impact of fewer surgeries due to the spread of COVID-19 was also evident in the current quarter, with total sales of consumables down 2.7% year on year. Meanwhile, demand increased for some products, including PPE, diabetes-related products, and PCR testing equipment. - FY2021-Q1MaterialisedAnnual report
「Total consumables revenue, the growth driver, decreased 5.1% year on year due to the impact of a decline in surgical cases associated with the spread of COVID-19.」
The impact of fewer surgeries due to the spread of COVID-19 was also evident in the current quarter, with total sales of consumables down 5.1% year on year. - FY2020MaterialisedAnnual report
「Based on these factors, the company estimated that sales in the medical equipment business were reduced by approximately ¥1.9 billion by the coronavirus during the fourth quarter of the current consolidated fiscal year. Although sales had grown steadily, mainly in consumables, through the cumulative third quarter of the current consolidated fiscal year, the upward trend in revenue was halted in the fourth quarter.」
The company estimates that the postponement of surgeries and patients refraining from seeking medical care due to the spread of COVID-19 actually occurred and reduced fourth-quarter sales in the medical equipment business by approximately ¥1.9 billion. - FY2020-Q3First statedAnnual report
「The company will continue to closely monitor the future impact on its business from the spread of the novel coronavirus.」
The company disclosed for the first time the business impact of the spread of COVID-19 and stated that it would closely monitor developments going forward. It did not state the amount of the impact or the actual business impact.